Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "obstructive-sleep-apnea"

16 News Found

Shaquille O’Neal partners with Lilly in National Awareness push for Zepbound
News | June 11, 2026

Shaquille O’Neal partners with Lilly in National Awareness push for Zepbound

The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed


Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide
News | June 09, 2026

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format


Lilly’s “triple agonist” drug delivers striking weight loss & broad health gains in late-stage trials
News | June 09, 2026

Lilly’s “triple agonist” drug delivers striking weight loss & broad health gains in late-stage trials

Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems


Eli Lilly secures full PBM coverage for obesity drug portfolio expanding access to millions
News | May 29, 2026

Eli Lilly secures full PBM coverage for obesity drug portfolio expanding access to millions

The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach


Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109
News | April 08, 2026

Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109

The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved


Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option
News | March 17, 2026

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect


Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
News | December 02, 2025

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

Patients can now get the starting 2.5 mg dose for $299 per month


Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness
News | October 31, 2025

Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness

Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their


LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
Supply Chain | October 30, 2025

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials


Cipla to sell Lilly's weight-loss drug under new brand in India
News | October 24, 2025

Cipla to sell Lilly's weight-loss drug under new brand in India

Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors